The Global Helicobacter Pylori Diagnostics Market, by Diagnosis Type (Invasive (Immunoassay, Rapid Urease Test, and Histology) and Non-invasive (Stool Antigen Assay, Serology Tests, and Urea Breath Test)), by End Users (Hospitals, Clinics, Diagnostic Laboratories, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) estimated to be valued at US$ 437.3 million in 2017, and is projected to exhibit a CAGR of 7.1% over the forecast period (2018 – 2026).
New product approval and launches by market players to sustain in the competitive global helicobacter pylori diagnostics market, is expected to aid in growth of the market. For instance, in 2016, Diasorin S.P.A. launched fully automated solution, LIASION, for H. pylori detection, intended for markets outside the U.S. In the same year, Exalenz Bioscience received U.S. Food and Drug Administration (FDA) marketing clearance for its BreathID Lab System and breath-test kits, developed for H. pylori bacterium detection. Moreover, in March 2018, the company received approval from the U.S. FDA to market its lab system and its point-of-care device for H. pylori detection in pediatric patients. Moreover, inorganic strategies of market players are also propelling the market growth.
Browse Market Data 27 Tables and 30 Figures spread through 167 Pages and in-depth TOC on "Helicobacter Pylori Diagnostics Market, by Test Type (Invasive (Immunoassay, Rapid Urease Test and Histology) and Non-invasive (Stool Antigen Assay, Serology Tests and Urea Breath Test)), by End Users (Hospitals, Clinics, Diagnostic Laboratories and Others) and by Region - Global Forecast to 2026”
To know the latest trends and insights related to Helicobacter pylori diagnostics market, click the link below:
https://www.coherentmarketinsights.com/market-insight/helicobacter-pylori-diagnostics-market-1874
Increasing prevalence of Helicobacter pylori in emerging economies is propelling demand for Helicobacter pylori diagnostic assay kits. For instance, according to Faculty of Medicine of The Chinese University of Hong Kong, 2017, Africa has the highest prevalence of Helicobacter pylori infections (which is around 79%). Moreover, unmet needs of detection and treatment is very high, as the there is no direct marketing of the products by market player and products are made available by the government only. Countries with declining incidence of Helicobacter pylori infection are also engaged in complete eradication of infection. Eradication is supported by various government initiatives such as to provide diagnostics test at lower rates and increasing screening programs. For instance, in 2013, the Japanese government approved national health insurance coverage for antibiotic treatment for H. pylori infection in patients with chronic gastritis and diagnosed by endoscopic method. Furthermore, the sensitivity and specificity of diagnostic assays are studied by universities and research institutes to improve the available test kits. Such studies show that invasive methods are more accurate. For instance, rapid urease test have sensitivity and specificity of 80-95% and 97-99% respectively, and, immunohistochemistry based assay kits displays >97% and 100% of sensitivity and specificity.
Key takeaways of the Helicobacter Pylori diagnostics Market:
- The global Helicobacter pylori diagnostics market is expected to expand at a CAGR of 7.1% during the forecast period (2018 – 2026), owing to increasing demand for point-of-care testing devices, for early detection of the disease.
- Invasive segment is expected to be dominant in test types, owing to introduction of better diagnostic assay with high sensitivity and specificity
- North America holds the dominant position in the regional segment, owing to increasing adoption of H. pylori eradication programs leading to high demand for H. Pylori diagnostic test products.
- Some of the major players operating in the global Helicobacter pylori diagnostics market include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., Diasorin S.P.A., Quidel Corporation, F. Hoffmann-La Roche Ltd.(Ventana Medical Systems, Inc.), Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Abbott Laboratories, Cardinal Health, Inc., and Halyard Health, Inc.
